{
 "drug": "Bendamustine Hydrochloride Injection, Solution",
 "asOf": "2026-08-25",
 "status": "discontinuing",
 "since": "07/23/2026",
 "dayN": 33,
 "cat": "Oncology",
 "companies": [
  "Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)"
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "07/23/2026",
   "update_type": "New",
   "initial_posting_date": "07/23/2026",
   "package_ndc": "63459-390-08",
   "generic_name": "Bendamustine Hydrochloride Injection, Solution",
   "contact_info": "(610) 344-0200",
   "related_info": "A business decision has been made to discontinue manufacture of the drug.",
   "openfda": {
    "application_number": [
     "NDA022249"
    ],
    "brand_name": [
     "TREANDA"
    ],
    "generic_name": [
     "BENDAMUSTINE HYDROCHLORIDE"
    ],
    "manufacturer_name": [
     "Cephalon, LLC"
    ],
    "product_ndc": [
     "63459-390",
     "63459-395",
     "63459-396",
     "63459-391"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAVENOUS"
    ],
    "substance_name": [
     "BENDAMUSTINE HYDROCHLORIDE"
    ],
    "rxcui": [
     "1805001",
     "1805004",
     "1805007",
     "1805009",
     "1805011",
     "1805012",
     "1805015",
     "1805016"
    ],
    "spl_id": [
     "77ae475d-2d59-4fe2-8de7-833b6fc9d51a"
    ],
    "spl_set_id": [
     "39d53698-57fa-7c99-fc5b-f52a55684826"
    ],
    "package_ndc": [
     "63459-395-02",
     "63459-396-02",
     "63459-390-08",
     "63459-391-20"
    ],
    "unii": [
     "981Y8SX18M"
    ]
   },
   "update_date": "07/23/2026",
   "therapeutic_category": [
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Treanda, Injection, Solution, 25 mg/5 mL, 1 vial, Single-Dose in 1 carton (NDC 63459-390-08)",
   "company_name": "Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)",
   "status": "To Be Discontinued"
  }
 ]
}